Prognostic Role of Tumor Microenvironment in DLBCL and Relation to Patients’ Clinical Outcome: A Clinical and Immunohistochemical Study

Table 2

The relation between T lymphocytic prognostic markers CD4 and CD8 and the following parameters: age, gender, bulky diseases, B symptoms, anemia, LDH, performance status, extranodal involvement, bone marrow and CNS involvement, stage, IPI, Ki67, BCL2, relapse, overall survival, and therapy response.

	CD4		value	CD8		value
	Low Ex	High Ex		Low Ex	High Ex
Age
0-59	49.2%	13.8%	0.916	53.8%	9.2%	0.545
+=60	29.2%	7.7%		30.8%	6.2%
Gender
Male	40.0%	16.9%	0.065	49.2%	7.7%	0.631
Female	38.5%	4.6%		35.4%	7.7%
Bulky dis
-ve	63.1%	18.5%	0.494	66.2%	15.4%	0.109
+ve	15.4%	3.1%		18.5%	0.0%
B symptoms
-ve	53.8%	20.0%	0.062	60.0%	13.8%	0.196
+ve	24.6%	1.5%		24.6%	1.5%
Anemia
-ve	50.8%	15.4%	0.448	58.5%	7.7%	0.241
+ve	27.7%	6.2%		26.2%	7.7%
LDH
Normal	4.6%	1.5%	0.631	7.3%	0.0%	0.504
High	73.8%	20.0%		78.5%	15.4%
Performance status
1	61.5%	16.9%	0.864	64.6%	13.8%	0.615
2	15.4%	4.6%		18.5%	1.5%
3	1.5%	0.0%		1.5%	0.0%
Extranodal involvement
0	60.0%	12.3%	0.235	61.5%	10.8%	0.569
1	15.4%	6.2%		16.9%	4.6%
2	3.1%	3.1%		6.2%	0.0%
Bone marrow and CNS involvement
-ve	69.2%	20.0%	0.528	73.8%	15.4%	0.291
+ve	9.2%	1.5%		10.8%	0.0%
Stage
1	6.2%	4.6%	0.427	7.7%	3.1%	0.387
2	9.2%	1.5%		10.8%	0.0%
3	40.0%	7.7%		38.5%	9.2%
4	23.1%	7.7%		27.7%	3.1%
IPI
1-2	50.8%	10.8%	0.316	50.8%	10.8%	0.411
3-4	27.7%	10.8%		33.8%	4.6%
Ki67
Low exp.	15.4%	3.1%	0.494	13.8%	4.6%	0.267
High exp.	63.1%	18.5%		70.8%	10.8%
BCl2
Low exp.	26.2%	4.6%	0.306	24.6%	6.2%	0.365
High exp.	52.3%	16.9%		60.0%	9.2%
Relapse
No	55.4%	13.8%	0.645	56.9%	12.3%	0.387
1-12 m	9.2%	4.6%		13.8%	0.0%
=+13 m	13.8%	3.1%		13.8%	3.1%
Overall survival
1-12 m	24.6%	6.2%	0.539	26.2%	4.6%	0.913
13-24 m	16.9%	7.7%		21.5%	3.1%
=+25	36.9%	7.7%		36.9%	7.7%
Therapy response
Regressive	16.9%	6.2%	0.581	20.0%	3.1%	0.867
Stationary	21.5%	3.1%		21.5%	3.1%
Progressive	40.0%	12.3%		43.1%	9.2%